BV
Bavarian Nordic A/S
BVNRY · OTC
$10.50 +0.12% (+$0.01)
1M +13.36%
Market Cap 15.6B kr
P/E Ratio 10.04x
Div. Yield -
ROE 12.00%
Bulios Fair Price
$15.29
45.7% upside
Current Price
$10.5
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BVNRY is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
7/9Valuation
96 /100
Cheap EV/EBITDA 5.68x
P/S 2.57x
P/B 1.18x
Growth
100 /100
Growing Book val. growth 21.64%
Rev. growth 23.49%
FCF growth N/A
Profitability
91 /100
Strong Net margin 25.64%
Op. margin 16.57%
FCF margin 20.21%
Quality
47 /100
Average ROE 12.00%
ROA 10.58%
Asset turnover 0.41x
Debt
100 /100
Low Current ratio 6.53x
Int. coverage 137.78x
Net debt/EBITDA -0.24x
Stability
32 /100
Unstable Rev. volatility 76.93%
EPS volatility 285.42%
Profitable years 3
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BVNRY
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Paul John Chaplin
Employees
1,795
Headquarters
Hellerup